Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3251]

Positive CHMP opinion recommends ibrutinib for the treatment of Waldenström’s macroglobulinemia

Positive CHMP opinion recommends ibrutinib for the treatment of Waldenström’s macroglobulinemia

Circulating tumour DNA in blood predicts recurrence of common lymphoma type

Circulating tumour DNA in blood predicts recurrence of common lymphoma type

Insights into a signalling process that enhances the effectiveness of cancer immunotherapy

Insights into a signalling process that enhances the effectiveness of cancer immunotherapy

Adding elotuzumab significantly reduces risk of progression for relapsed multiple myeloma

Adding elotuzumab significantly reduces risk of progression for relapsed multiple myeloma

Cell movement dynamics sheds light on cancer therapy

Cell movement dynamics sheds light on cancer therapy

Discovery could help reverse glucocorticoid resistance in some young leukaemia patients

Discovery could help reverse glucocorticoid resistance in some young leukaemia patients

AACR 2015: Pembrolizumab safe, with signs of clinical benefit, for patients with malignant pleural mesothelioma

AACR 2015: Pembrolizumab safe, with signs of clinical benefit, for patients with malignant pleural mesothelioma

AACR 2015: New T cell–based immunotherapy shows promise for lethal stem cell transplant complication

AACR 2015: New T cell–based immunotherapy shows promise for lethal stem cell transplant complication

AACR 2015: Pembrolizumab is better than ipilimumab for advanced melanoma in phase III trial

AACR 2015: Pembrolizumab is better than ipilimumab for advanced melanoma in phase III trial

Active Pin1 is a target for all-trans retinoic acid in leukaemia and breast cancer

Active Pin1 is a target for all-trans retinoic acid in leukaemia and breast cancer

More from ecancer